Robert F. Vroom

Robert F. Vroom

Robert Vroom has been litigating intellectual property cases for nearly a decade.  Mr. Vroom’s practice has focused on pharmaceutical litigation related to the Hatch-Waxman Act.  He has also litigated cases in a wide variety of arts, including cosmetic emulsions and toilet training devices for children.     

Mr. Vroom’s experience includes the presentation of a case at trial, all facets of pre-trial litigation, and alternative dispute resolution.   Mr. Vroom is also experienced in appellate practice before the Federal Circuit and in conducting interference proceedings before the United States Patent and Trademark Office.

Additionally, Mr. Vroom has provided counseling to clients regarding possible infringement or validity issues, patent prosecution for major international clients, and transactional work relating to intellectual property.

Mr. Vroom has served as the senior editor of Unfair Competition and the ITC, a handbook on practice before the United States International Trade Commission in Section 337 investigations. He has also been recognized for his service to the U.S. District Court for the District of Columbia’s civil pro bono program, in which he served as lead counsel for a plaintiff alleging wrongful termination.

Prior to attending law school at the University of Virginia, Mr. Vroom obtained a Master of Science degree in oceanography from the Scripps Institution of Oceanography at the University of California, San Diego.   While at Scripps, Mr. Vroom studied the chemistry of mud-volcanoes on accretionary prisms and served as a scientific member on several oceanographic cruises, including a two-week cruise south of Taiwan.

At Florida State University, Mr. Vroom received a Bachelor of Science degree in chemistry with an inter-disciplinary minor in physics and calculus.   Mr. Vroom investigated stereo-chemical interactions of compounds, which involved organic synthesis, computer modeling and instrumental analysis.

Representative litigation matters include:

UCB v. KV Pharmaceutical Company (D. Del.) (case involving generic version of Metadate® CD) (currently pending)

Alza Corporation v. Andrx Pharmaceuticals (D. Del.) (case involving generic version of Concerta®; district court held that product made by Kenyon’s client Andrx would not infringe Alza’s patent and that Alza’s patent was invalid) (appeal pending)

Janssen v. KV Pharmaceutical Company  (D.N.J.) (case involving generic version of Razadyne® ER; after favorable Markman ruling, the matter was settled and dismissed with prejudice)

Shire v. Impax (D. Del.) (case involving generic version of Adderall® XR; after favorable Markman ruling, the matter was settled and dismissed with prejudice)

Novo Nordisk Pharmaceuticals, Inc. v. Bio-Technology General Corp. and Teva Pharmaceuticals USA, Inc. (D. Del. and Fed. Cir.) (case involving human growth hormone product made by Kenyon’s clients BTG and Teva; district court held that Novo’s patent was invalid and unenforceable and Federal Circuit affirmed)

Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline, PLC (E.D. Va. and Fed. Cir.) (case involving generic version of Augmentin®; district court held that GSK’s patents were invalid and Federal Circuit affirmed)

Revlon v. Estee Lauder (S.D.N.Y.) (case involving cosmetic emulsions; after magistrate’s favorable report and recommendations concerning claim construction and summary judgment of non-infringement, the matter was settled and dismissed with prejudice)